An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 6, 2010, Pages 1065-1070

  Naito, Seiji ^a   Tsukamoto, Taiji ^b   Usami, Michiyuki ^c   Fujimoto, Hiroyuki ^d   Akaza, Hideyuki ^e  

^a KYUSHU UNIVERSITY   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Chemotherapy; Cytokine refractory; Phase II Trial; Renal cell carcinoma; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALPHA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 2;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER IMMUNOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROPENIA; FATIGUE; FEMALE; GLUCOSURIA; HEMATOCRIT; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPOALBUMINEMIA; HYPONATREMIA; JAPANESE; KIDNEY CARCINOMA; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; TASTE DISORDER; THROMBOCYTOPENIA; TUMOR REGRESSION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; CYTOKINES; DISEASE PROGRESSION; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERFERONS; INTERLEUKIN-2; JAPAN; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; OXONIC ACID; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 78149411848     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1262-8     Document Type: Article

References (31)

1. A Mancuso CN Sternberg 2005 New treatments for metastatic kidney cancer Can J Urol 12 Suppl 1 66 70 15780170 discussion 105
2. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai F Rolland T Demkow TE Hutson M Gore S Freeman B Schwartz M Shan R Simantov RM Bukowski 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 1:CAS:528:DC%2BD2sXksVKitg%3D%3D 10.1056/NEJMoa060655 17215530 (Pubitemid 46089673)
3. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312-3318
4. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski O Rixe S Oudard S Negrier C Szczylik ST Kim I Chen PW Bycott CM Baum RA Figlin 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 10.1056/NEJMoa065044 17215529 (Pubitemid 46089672)
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garciadel-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 22:3584-3590
6. T Shirasaka Y Shimamato H Ohshimo M Yamaguchi T Kato K Yonekura M Fukushima 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548 557 1:CAS:528:DyaK28Xltleru78%3D 10.1097/00001813-199607000-00010 8862723
7. K Tatsumi M Fukushima T Shirasaka S Fujii 1987 Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res 78 748 755 1:CAS:528:DyaL2sXlvFSntL8%3D 3114201
8. T Shirasaka Y Shimamoto M Fukushima 1993 Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004 4009 1:CAS:528:DyaK3sXmtFKqsrk%3D 7689420
9. W Koizumi M Kurihara S Nakano K Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191 197 1:CAS:528: DC%2BD3cXjvVeitr4%3D 10.1159/000012099 10765119
10. K Shirao A Ohtsu H Takada Y Mitachi K Hirakawa N Horikoshi T Okamura K Hirata S Saitoh H Isomoto A Satoh 2004 Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma Cancer 100 2355 2361 1:CAS:528: DC%2BD2cXltFajsr4%3D 10.1002/cncr.20277 15160338 (Pubitemid 38657882)
11. M Kawahara K Furuse Y Segawa K Yoshimori K Matsui S Kudoh K Hasegawa H Niitani 2001 Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer Br J Cancer 85 939 943 1:CAS:528:DC%2BD3MXot1SktLg%3D 10.1054/bjoc.2001.2031 11592762 (Pubitemid 33015993)
12. T Saeki S Takashima M Sano N Horikoshi S Miura S Shimizu K Morimoto M Kimura H Aoyama J Ota S Noguchi T Taguchi 2004 A phase II study of S-1 in patients with metastatic breast cancer-a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group Breast Cancer 11 194 202 10.1007/BF02968301
13. Y Inuyama A Kida M Tsukuda N Kohno B Satake 2001 Late phase II study of S-1 in patients with advanced head and neck cancer Gan To Kagaku Ryoho 28 1381 1390 1:STN:280:DC%2BD3Mrntl2isg%3D%3D 11681245
14. T Okusaka A Funakoshi J Furuse N Boku K Yamao S Ohkawa H Saito 2008 A late phase II study of S-1 for metastatic pancreatic cancer Cancer Chemother Pharmacol 61 615 621 1:CAS:528:DC%2BD1cXjsFWktw%3D%3D 10.1007/s00280-007-0514-8 17520253
15. Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62:849-855
16. Y Koyama 1993 Japan society for cancer therapy: criteria for the evaluation of the clinical effects of solid cancer chemotherapy J Jpn Soc Cancer Ther 28 101 130
17. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
18. PP Rickham 1964 HUMAN EXPERIMENTATION. CODE OF ETHICS OF THE WORLD MEDICAL ASSOCIATION. DECLARATION OF HELSINKI Br Med J 2 177 1:STN:280: DyaF2c7gvVygsA%3D%3D 10.1136/bmj.2.5402.177 14150898
19. ELMP Kaplan 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
20. R von Roemeling JT Rabatin EE Fraley WJ Hrushesky 1988 Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion J Urol 139 259 262
21. FH Dexeus CJ Logothetis A Sella R Amato R Kilbourn S Ogden A Striegel J Kwan RA Newman 1991 Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma J Urol 146 709 713 1:STN:280: DyaK3MzktFyrug%3D%3D 1831513
22. JA Ellerhorst A Sella RJ Amato SM Tu RE Millikan LD Finn M Banks CJ Logothetis 1997 Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma Cancer 80 2128 2132 1:CAS:528:DyaK2sXnvV2itbs%3D 10.1002/(SICI)1097- 0142(19971201)80:11<2128::AID-CNCR12>3.0.CO;2-0 9392335 (Pubitemid 27506026)
23. S Negrier A Caty T Lesimple JY Douillard B Escudier JF Rossi P Viens F Gomez 2000 Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer J Clin Oncol 18 4009 4015 1:CAS:528: DC%2BD3MXktFegtg%3D%3D 11118461
24. BI Rini NJ Vogelzang MC Dumas JL Wade 3rd DA Taber WM Stadler 2000 Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer J Clin Oncol 18 2419 2426 1:CAS:528:DC%2BD3cXkvFWrsbw%3D 10856102
25. F Masuda J Nakada I Kondo N Furuta 1992 Adjuvant chemotherapy with vinblastine, adriamycin, and UFT for renal-cell carcinoma Cancer Chemother Pharmacol 30 477 479 1:STN:280:DyaK3s%2FgvVKqtQ%3D%3D 10.1007/BF00685600 1394804
26. A Yagoda B Abi-Rached D Petrylak 1995 Chemotherapy for advanced renal-cell carcinoma: 1983-1993 Semin Oncol 22 42 60 1:STN:280: DyaK2M7lvVyqug%3D%3D 7855619
27. WC Mertens EA Eisenhauer M Moore P Venner D Stewart A Muldal D Wong 1993 Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group Ann Oncol 4 331 332 1:STN:280:DyaK3s3pvVKqtA%3D%3D 8518225 (Pubitemid 23139376)
28. PH De Mulder L Weissbach G Jakse R Osieka J Blatter 1996 Gemcitabine: a phase II study in patients with advanced renal cancer Cancer Chemother Pharmacol 37 491 495 10.1007/s002800050417 8599874 (Pubitemid 26057437)
29. NM Tannir PF Thall CS Ng X Wang L Wooten A Siefker-Radtke P Mathew L Pagliaro C Wood E Jonasch 2008 A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents J Urol 180 867 872 1:CAS:528:DC%2BD1cXhtVKmsbjM 10.1016/j.juro.2008.05.017 18635226 discussion 872
30. RJ Motzer BI Rini RM Bukowski BD Curti DJ George GR Hudes BG Redman KA Margolin JR Merchan G Wilding MS Ginsberg J Bacik ST Kim CM Baum MD Michaelson 2006 Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2516 2524 1:CAS:528:DC%2BD28XlsV2rtLk%3D 10.1001/jama.295.21.2516 16757724 (Pubitemid 43854967)
31. RJ Motzer MD Michaelson BG Redman GR Hudes G Wilding RA Figlin MS Ginsberg ST Kim CM Baum SE DePrimo JZ Li CL Bello CP Theuer DJ George BI Rini 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 16 24 1:CAS:528: DC%2BD28Xot1ChtA%3D%3D 10.1200/JCO.2005.02.2574 16330672 (Pubitemid 46630489)